NEW YORK (GenomeWeb News) – Pressure BioSciences has raised around $1.7 million through a private placement of units, the firm disclosed today in a filing with the US Securities and Exchange Commission.

The company said that it sold 4,257 units at a price of $400 per unit. The $1.7 million it raised is the first tranche of a targeted $2 million, said Pressure Bio, adding that it expects to close one or more tranches on or before Feb. 28, 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.